2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid, often abbreviated as **DMQ**, is a heterocyclic compound with a specific structure that makes it an interesting target for research. Here's a breakdown:
**Structure:**
* **Quinoline:** The core structure is a quinoline, a bicyclic aromatic ring system containing both benzene and pyridine rings.
* **Pyrazole:** Attached to the quinoline ring is a pyrazole, another heterocyclic ring system.
* **Substitutions:** The pyrazole ring has two methyl groups (CH3) at positions 1 and 5, and the quinoline ring has a carboxylic acid group (-COOH) at position 4.
**Importance in Research:**
DMQ is important because of its potential applications in various fields, including:
* **Medicinal Chemistry:**
* **Antimicrobial activity:** DMQ has shown promising antibacterial and antifungal activity against a range of microorganisms. This makes it a potential candidate for developing new antibiotics.
* **Anti-inflammatory activity:** Studies have shown that DMQ possesses anti-inflammatory properties, potentially beneficial for treating various inflammatory conditions.
* **Antioxidant activity:** DMQ has been reported to exhibit antioxidant activity, which could protect cells from damage caused by free radicals.
* **Material Science:**
* **Organic semiconductors:** DMQ's conjugated structure (alternating single and double bonds) makes it suitable for use in organic electronics as a building block for organic semiconductors. This opens possibilities for developing new and flexible electronic devices.
* **Luminescent materials:** DMQ's structure can also contribute to its luminescent properties, leading to applications in organic light-emitting diodes (OLEDs) and other optoelectronic devices.
* **Analytical Chemistry:**
* **Fluorescence probes:** DMQ's fluorescent properties can be exploited for developing sensors and probes for detecting specific molecules or ions in biological and environmental samples.
**Current Research:**
Researchers are actively investigating DMQ's properties and potential applications further. This includes:
* **Synthesizing new derivatives:** Modifying DMQ's structure to create new derivatives with enhanced biological activity or different optical properties.
* **Understanding its mechanism of action:** Studying how DMQ interacts with biological targets to understand its biological effects.
* **Developing new applications:** Exploring novel uses for DMQ, such as in drug delivery systems or bioimaging techniques.
**Overall, 2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid (DMQ) is a promising molecule with potential applications in diverse fields. Ongoing research will further clarify its properties and pave the way for developing innovative technologies and treatments.**
ID Source | ID |
---|---|
PubMed CID | 3164943 |
CHEMBL ID | 1599774 |
CHEBI ID | 120051 |
Synonym |
---|
MLS000715100 |
smr000275079 |
2-(1,5-dimethyl-1h-pyrazol-4-yl)quinoline-4-carboxylic acid |
STK310122 |
2-(1,5-dimethyl-1h-pyrazol-4-yl)-quinoline-4-carboxylic acid |
CHEBI:120051 |
AKOS000302471 |
2-(1,5-dimethylpyrazol-4-yl)quinoline-4-carboxylic acid |
HMS2703E05 |
BBL013056 |
925145-52-4 |
2-(1,5-dimethyl-1 h-pyrazol-4-yl)-quinoline-4-carboxylic acid |
CHEMBL1599774 |
Q27207853 |
2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid |
mfcd04969957 |
VS-03651 |
2-(1,5-dimethyl-1h-pyrazol-4-yl)quinoline-4-carboxylicacid |
EN300-229688 |
CS-0240687 |
DTXSID801325186 |
2-(1,5-dimethyl-1h-pyrazol-4-yl)-4-quinolinecarboxylic acid |
Class | Description |
---|---|
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 44.6684 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |